Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
NCT06162221 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors as a monotherapy or combined with Standard(s) of Care (SOC) or with each other. The first four subprotocols include the following: Subprotocol A: RMC-6291 +/- RMC-6236 + SOC Subprotocol B: RMC-6236 + SOC Subprotocol C: RMC-9805 +/- RMC-6236 + SOC Subprotocol D: RMC-9805
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Carboplatin
- DRUG Cisplatin
- DRUG RMC-6291
- DRUG RMC-6236
Study Locations (20)
California
- City of Hope - Duarte — Duarte
- City of Hope - Lennar — Irvine
- UC Davis, Davis Comprehensive Cancer Center — Sacramento
- University of California, San Diego Moores Cancer Center — San Diego
- UCSF Medical Center - Mission Bay — San Francisco
- Stanford University - Stanford Cancer Institute — Stanford
New York
- New York University Langone Health — New York
- Icahn School of Medicine at Mount Sinai — New York
- Columbia University Medical Center — New York
- Clinical Research Alliance — Westbury
Florida
- Boca Raton Clinical Research Associates — Plantation
- Cancer Specialists of North Florida — Saint Augustine
- H Lee Moffitt Cancer Center and Research Institute — Tampa
Arizona
- Banner MD Anderson Cancer Center — Gilbert
District of Columbia
- Georgetown University Medical Center — Washington D.C.
Massachusetts
- Dana Farber Cancer Institute — Boston
Michigan
- Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion) — Detroit
Montana
- Intermountain Health - St. Vincent Frontier Cancer Center — Billings
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 616 participants |
| Start Date | 2024-01-18 |
| Est. Completion | 2028-12 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06162221
The ClinicalTrials.gov registry entry for NCT06162221 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 616 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Revolution Medicines, which has 66 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 5 conditions, with Non-Small Cell Lung Cancer, NSCLC appearing as the primary indexed condition, and to 5 interventions — of which Pembrolizumab is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06162221 reports 20 study locations spanning 10 distinct geographic areas — top geographies include California, New York, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06162221 about?
NCT06162221 is a clinical study titled "Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC". The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors as a monotherapy or combined with Standard(s) of Care (SOC) or with each other. The first four subprotocols include the following: Subpr...
What is the current status of trial NCT06162221?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 616 participants. The study started on 2024-01-18. Estimated completion is 2028-12.
What conditions does trial NCT06162221 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer, RAS G12D-mutated NSCLC. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06162221?
The interventions under investigation include: Pembrolizumab (DRUG), Carboplatin (DRUG), Cisplatin (DRUG), RMC-6291 (DRUG), RMC-6236 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06162221?
This trial is sponsored by Revolution Medicines, which has 66 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06162221 being conducted?
This trial has 20 study locations across Arizona, California, District of Columbia, Florida, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.